Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach

Roberto Paciotti1, Mariangela Agamennone2, Cecilia Coletti2

  • 1Department of Pharmacy, Università "G. D'Annunzio" Di Chieti-Pescara, Chieti, Italy. r.paciotti@unich.it.

Insights

Researchers computationally characterized programmed cell death protein 1 ligand (PD-L1) binding sites using novel methods. This study identified key interaction regions and a potential pharmacophore for developing new PD-L1 inhibitors.

Area of Science:

  • Computational chemistry
  • Immunology
  • Drug discovery

Background:

  • Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are crucial immune checkpoints.
  • Tumor cells exploit the PD-1/PD-L1 pathway to evade immune responses.
  • Anti-PD-L1 small drugs are promising cancer therapeutics, but their binding site characteristics are underexplored.

Purpose of the Study:

  • To computationally characterize the binding sites of PD-L1.
  • To identify key interaction regions in PD-L1 for protein-protein and ligand-protein interactions.
  • To propose a pharmacophore for the development of novel PD-L1 inhibitors.

Main Methods:

  • Utilized a novel computational protocol combining ab initio Fragment Molecular Orbital (FMO) and GRID-DRY approaches.
  • Analyzed PD-1/PD-L1 and PD-L1/BMS-ligand complexes.
  • Calculated pair-residue and ligand-residue interactions with ab initio accuracy and investigated hydrophobic interactions.

Main Results:

  • Identified three specific hot regions involved in PD-1/PD-L1 and PD-L1/BMS-ligand interactions.
  • The GRID-DRY protocol quantitatively assessed energy contributions of ligand atoms to hydrophobic interactions.
  • Results align with previous theoretical and experimental findings.

Conclusions:

  • The study provides detailed insights into PD-L1 binding site characteristics.
  • The identified pharmacophore can guide the design of more effective anti-PD-L1 small drugs.
  • This computational approach enhances understanding for targeted cancer immunotherapy development.

Related Concept Videos